Health-Related Quality of Life in the Gender, Race, And Clinical Experience Trial

Table 1

Baseline demographics and disease characteristics by sex and race^a.

Parameter	Women 𝑛=287	Men 𝑛=142	Black 𝑛=264	Hispanic 𝑛=96	White 𝑛=65
Age, mean (SE), years	41.7 (0.63)	45.2 (0.75)	43.0 (0.62)	40.3 (1.05)	45.5 (1.13)
Gender, n (%)
Female	287 (100)	—	191 (72.3)	60 (62.5)	34 (52.3)
Male	—	142 (100)	73 (27.7)	36 (37.5)	31 (47.7)
BMI, mean (SE), kg/m^2	28.2 (0.44)	25.4 (0.42)	27.6 (0.44)	26.8 (0.58)	26.7 (0.88)
Duration of infection, mean (SE), years	10.9 (0.32)	12.2 (0.49)	11.0 (0.34)	10.5 (0.58)	13.8 (0.66)
Viral load, mean (SE), log10 copies/mL	4.65 (0.05)	4.73 (0.07)	4.66 (0.06)	4.68 (0.09)	4.73 (0.10)
CD4+ count, median (range), cells/mm^3	210 (1, 868)	175 (2, 1125)	179 (1, 868)	208 (1, 1125)	249 (6, 826)
CDC Class C, n (%)	102 (35.5)	67 (47.2)	111 (42.0)	33 (34.4)	22 (33.8)
Prior use of ≥2 PIs, n (%)	168 (58.5)	92 (64.8)	156 (59.1)	60 (62.5)	42 (64.6)
PSS of the OBR^b, mean (SD)	2.0 (0.65)	2.0 (0.81)	2.0 (0.72)	1.9 (0.67)	2.0 (0.67)
Hepatitis B surface antigen (positive), n (%)	12 (4.2)	7 (4.9)	15 (5.7)	3 (3.1)	1 (1.5)
Hepatitis C antibody (positive), n (%)	39 (13.6)	25 (17.6)	41 (15.5)	12 (12.5)	11 (16.9)

^aTwo women and two men self-identified as Asian or other and were not included in the analysis by race. ^bBy virco TYPE; SE: standard error; BMI: body mass index; CDC: Centers for Disease Control and Prevention; PI: protease inhibitor; PSS: phenotypic susceptibility score; OBR: optimized background regimen; SD: standard deviation.